1. Hallberg, B. and Palmer, R.H. (2013) Mechanistic in- sight into ALK receptor tyrosine kinase in human can- cer biology. Nat. Rev. Cancer 13, 685–700
2. Morris, S.W., Kirstein, M.N., Valentine, M.B., Dittmer, K.G., Shapiro, D.N., Saltman, D.L., and Look, A.T. (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymph- oma. Science 263, 1281–1284
3. Shiota, M., Fujimoto, J., Semba, T., Satoh, H., Yamamoto, T., and Mori, S. (1994) Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9, 1567–1574
4. Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., Hu, Y., Tan, Z., Stokes, M., Sullivan, L., Mitchell, J., Wetzel, R., Macneill, J., Ren, J.M., Yuan, J., Bakalarski, C.E., Villen, J., Kornhauser, J.M., Smith, B., Li, D., Zhou, X., Gygi, S.P., Gu, T.L., Polakiewicz, R.D., Rush, J., and Comb, M.J. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kin- ases in lung cancer. Cell 131, 1190–1203
5. Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., and Mano, H. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566
6. Takeuchi, K., Soda, M., Togashi, Y., Ota, Y., Sekiguchi, Y., Hatano, S., Asaka, R., Noguchi, M., and Mano, H. (2011) Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymph- oma. Haematologica 96, 464–467
7. Kelly, L.M., Barila, G., Liu, P., Evdokimova, V.N., Trivedi, S., Panebianco, F., Gandhi, M., Carty, S.E., Hodak, S.P., Luo, J., Dacic, S., Yu, Y.P., Nikiforova, M.N., Ferris, R.L., Altschuler, D.L., and Nikiforov, Y.E. (2014) Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc. Natl. Acad. Sci. USA 111, 4233–4238
8. Chen, Y., Takita, J., Choi, Y.L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., Nakagawara, A., Hayashi, Y., Mano, H., and Ogawa, S. (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971–974
9. George, R.E., Sanda, T., Hanna, M., Fro¨hling, S., Luther, W., Zhang, J., Ahn, Y., Zhou, W., London, W.B., McGrady, P., Xue, L., Zozulya, S., Gregor, V.E., Webb, T.R., Gray, N.S., Gilliland, D.G., Diller, L., Greulich, H., Morris, S.W., Meyerson, M., and Look, A.T. (2008) Activating mutations in ALK pro- vide a therapeutic target in neuroblastoma. Nature 455, 975–978
10. Mosse´, Y.P., Laudenslager, M., Longo, L., Cole, K.A., Wood, A., Attiyeh, E.F., Laquaglia, M.J., Sennett, R., Lynch, J.E., Perri, P., Laureys, G., Speleman, F., Kim, C., Hou, C., Hakonarson, H., Torkamani, A., Schork, N.J., Brodeur, G.M., Tonini, G.P., Rappaport, E., Devoto, M., and Maris, J.M. (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930–935
11. Christensen, J.G., Zou, H.Y., Arango, M.E., Li, Q., Lee, J.H., McDonnell, S.R., Yamazaki, S., Alton, G.R., Mroczkowski, B., and Los, G. (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol. Cancer Ther. 6, 3314–3322
12. Kwak, E.L., Bang, Y.J., Camidge, D.R., Shaw, A.T., Solomon, B., Maki, R.G., Ou, S.H., Dezube, B.J., Ja¨nne, P.A., Costa, D.B., Varella-Garcia, M., Kim, W.H., Lynch, T.J., Fidias, P., Stubbs, H., Engelman, J.A., Sequist, L.V., Tan, W., Gandhi, L., Mino- Kenudson, M., Wei, G.C., Shreeve, S.M., Ratain, M.J., Settleman, J., Christensen, J.G., Haber, D.A., Wilner, K., Salgia, R., Shapiro, G.I., Clark, J.W., and Iafrate, A.J. (2010) Anaplastic lymphoma kinase inhib- ition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703
13. Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., Mori, S., Ratzkin, B., and Yamamoto, T. (1997) Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14, 439–449
14. Vernersson, E., Khoo, N.K., Henriksson, M.L., Roos, G., Palmer, R.H., and Hallberg, B. (2006) Characterization of the expression of the ALK receptor tyrosine kinase in mice. Gene Expr. Patterns 6, 448–461
15. Bazigou, E., Apitz, H., Johansson, J., Lore´n, C.E., Hirst, E.M., Chen, P.L., Palmer, R.H., and Salecker, I. (2007) Anterograde Jelly belly and Alk receptor tyro- sine kinase signaling mediates retinal axon targeting in Drosophila. Cell 128, 961–975
16. Lee, H.H., Norris, A., Weiss, J.B., and Frasch, M. (2003) Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers. Nature 425, 507–512
17. Liao, E.H., Hung, W., Abrams, B., and Zhen, M. (2004) An SCF-like ubiquitin ligase complex that con- trols presynaptic differentiation. Nature 430, 345–350
18. Bilsland, J.G., Wheeldon, A., Mead, A., Znamenskiy, P., Almond, S., Waters, K.A., Thakur, M., Beaumont, V., Bonnert, T.P., Heavens, R., Whiting, P., McAllister, G., and Munoz-Sanjuan, I. (2008) Behavioral and neurochemical alterations in mice defi- cient in anaplastic lymphoma kinase suggest therapeut- ic potential for psychiatric indications. Neuropsychopharmacology 33, 685–700
19. Orthofer, M., Valsesia, A., Ma¨gi, R., Wang, Q.P., Kaczanowska, J., Kozieradzki, I., Leopoldi, A., Cikes, D., Zopf, L.M., Tretiakov, E.O., Demetz, E., Hilbe, R., Boehm, A., Ticevic, M., No~ukas, M., Jais, A., Spirk, K., Clark, T., Amann, S., Lepamets, M., Neumayr, C., Arnold, C., Dou, Z., Kuhn, V., Novatchkova, M., Cronin, S.J.F., Tietge, U.J.F., Mu¨ller, S., Pospisilik, J.A., Nagy, V., Hui, C.C., Lazovic, J., Esterbauer, H., Hagelkruys, A., Tancevski, I., Kiefer, F.W., Harkany, T., Haubensak, W., Neely, G.G., Metspalu, A., Hager, J., Gheldof, N., and Penninger, J.M. (2020) Identification of ALK in thin- ness. Cell 181, 1246–1262.e1222
20. Sakamoto, K. and Kadomatsu, K. (2012) Midkine in the pathology of cancer, neural disease, and inflamma- tion. Pathol. Int. 62, 445–455
21. Stoica, G.E., Kuo, A., Powers, C., Bowden, E.T., Sale, E.B., Riegel, A.T., and Wellstein, A. (2002) Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J. Biol. Chem. 277, 35990–35998
22. Stoica, G.E., Kuo, A., Aigner, A., Sunitha, I., Souttou, B., Malerczyk, C., Caughey, D.J., Wen, D., Karavanov, A., Riegel, A.T., and Wellstein, A. (2001) Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J. Biol. Chem. 276, 16772–16779
23. Mathivet, T., Mazot, P., and Vigny, M. (2007) In con- trast to agonist monoclonal antibodies, both C-terminal truncated form and full length form of Pleiotrophin failed to activate vertebrate ALK (ana- plastic lymphoma kinase)? Cell Signal. 19, 2434–2443
24. Moog-Lutz, C., Degoutin, J., Gouzi, J.Y., Frobert, Y., Brunet-de Carvalho, N., Bureau, J., Cre´minon, C., and Vigny, M. (2005) Activation and inhibition of anaplas- tic lymphoma kinase receptor tyrosine kinase by mono- clonal antibodies and absence of agonist activity of pleiotrophin. J. Biol. Chem. 280, 26039–26048
25. Murray, P.B., Lax, I., Reshetnyak, A., Ligon, G.F., Lillquist, J.S., Natoli, E.J., Shi, X., Folta-Stogniew, E., Gunel, M., Alvarado, D., and Schlessinger, J. (2015) Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK. Sci. Signal. 8, ra6
26. Kadomatsu, K. and Sakamoto, K. (2014) Mechanisms of axon regeneration and its inhibition: roles of sul- fated glycans. Arch. Biochem. Biophys. 558, 36–41
27. Kadomatsu, K. and Sakamoto, K. (2014) Sulfated gly- cans in network rewiring and plasticity after neuronal injuries. Neurosci. Res. 78, 50–54
28. Sakamoto, K., Ozaki, T., Ko, Y.C., Tsai, C.F., Gong, Y., Morozumi, M., Ishikawa, Y., Uchimura, K., Nadanaka, S., Kitagawa, H., Zulueta, M.M.L., Bandaru, A., Tamura, J.I., Hung, S.C., and Kadomatsu, K. (2019) Glycan sulfation patterns define autophagy flux at axon tip via PTPRsigma-cortactin axis. Nat. Chem. Biol. 15, 699–709
29. Aricescu, A.R., McKinnell, I.W., Halfter, W., and Stoker, A.W. (2002) Heparan sulfate proteoglycans are ligands for receptor protein tyrosine phosphatase sigma. Mol. Cell. Biol. 22, 1881–1892
30. Shen, Y., Tenney, A.P., Busch, S.A., Horn, K.P., Cuascut, F.X., Liu, K., He, Z., Silver, J., and Flanagan, J.G. (2009) PTPsigma is a receptor for chon- droitin sulfate proteoglycan, an inhibitor of neural re- generation. Science 326, 592–596
31. Coles, C.H., Shen, Y., Tenney, A.P., Siebold, C., Sutton, G.C., Lu, W., Gallagher, J.T., Jones, E.Y., Flanagan, J.G., and Aricescu, A.R. (2011) Proteoglycan-specific molecular switch for RPTPr clustering and neuronal extension. Science 332, 484–488
32. Tran, A.P., Warren, P.M., and Silver, J. (2020) Regulation of autophagy by inhibitory CSPG interac- tions with receptor PTPr and its impact on plasticity and regeneration after spinal cord injury. Exp. Neurol. 328, 113276
33. Huang, H. (2018) Anaplastic Lymphoma Kinase (ALK) receptor tyrosine kinase: a catalytic receptor with many faces. Int. J. Mol. Sci. 19, 3448.
34. Souttou, B., Carvalho, N.B., Raulais, D., and Vigny, M. (2001) Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differenti- ation through the mitogen-activated protein kinase pathway. J. Biol. Chem. 276, 9526–9531
35. Trowbridge, J.M. and Gallo, R.L. (2002) Dermatan sulfate: new functions from an old glycosaminoglycan. Glycobiology 12, 117R–125R
36. Du¨ndar, M., Mu¨ller, T., Zhang, Q., Pan, J., Steinmann, B., Vodopiutz, J., Gruber, R., Sonoda, T., Krabichler, B., Utermann, G., Baenziger, J.U., Zhang, L., and Janecke, A.R. (2009) Loss of dermatan-4-sulfotransferase 1 func- tion results in adducted thumb-clubfoot syndrome. Am. J. Hum. Genet. 85, 873–882